Agents targeting cytotoxic T-lymphocyte antigen 4 (CTLA-4), programmed cell death protein 1 (PD-1), or programmed cell death protein ligand 1 (PD-L1) have transformed the approach to the management of numerous types of tumors, including HCC: in the landscape of advanced HCC systemic treatments, the combination of atezolizumab and bevacizumab (Atezo-Bev) actually stands as the first-line therapy, demonstrating superior survival outcomes compared to sorafenib [13,17,21]. Here, CTLA4 is linked to hepatocellular carcinoma.